Top

Published in:

01-01-2009

The CCR5 (−2135C/T) Polymorphism may be Associated with the Development of Kawasaki Disease in Korean Children

Authors: Won Kyoung Jhang, Mi-Jin Kang, Hyun-Seung Jin, Jinho Yu, Byoung-ju Kim, Bong Seong Kim, Jong-Keuk Lee, Eul-Ju Seo, Han-Wook Yoo, In Sook Park, Young Mi Hong, Soo-Jong Hong

Published in: Journal of Clinical Immunology | Issue 1/2009

Abstract

Background

Kawasaki disease (KD) is an acute vasculitis syndrome of unknown etiology that frequently affects small to medium size arteries. C-C chemokine receptor 5 (CCR5) is a chemokine receptor that binds C-C chemokines. This study investigated the association of the CCR5 (−2135C/T) polymorphism with KD in Korean children.

Methods

The study population consisted 189 Korean children with KD and 194 Korean children with congenital heart disease (CHD). CCR5 (−2135C/T) polymorphism genotypes were determined using the single-base extension method.

Results

The allele frequencies of the CCR5 (−2135C/T) polymorphism differed significantly between CHD children and KD children (−2135T/T, 16.75% vs. 30.05%, aOR 2.14, 95% CI 1.31–3.51). The tested laboratory parameters differed significantly between the KD and CHD groups. The development of coronary artery aneurysm in KD patients was not associated with the CCR5 polymorphism.

Conclusions

Our findings suggest that the T allele at the CCR5 (−2135C/T) polymorphism might be associated with the development of KD in Korean children but does not appear to be associated with the development of coronary artery aneurysm.

Desai A, Patel S, Book W. “Myocardial infarction” in adolescents: do we have the correct diagnosis? Pediatr Cardiol 2005;26:627–31. doi:10.1007/s00246-004-0864-5.PubMedCrossRef

Burns JC. Commentary: translation of Dr. Tomisaku Kawasaki’s original report of fifty patients in 1967. Pediatr Infect Dis J 2002;21:993–5. doi:10.1097/00006454-200211000-00002.PubMedCrossRef

Burgner D, Harnden A. Kawasaki disease: what is the epidemiology telling us about the etiology? Int J Infect Dis 2005;9:185–94. doi:10.1016/j.ijid.2005.03.002.PubMedCrossRef

Onouchi Y, Tamari M, Takahashi A, Tsunoda T, Yashiro M, Nakamura Y, et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet 2007;52:179–90. doi:10.1007/s10038-006-0092-3.PubMedCrossRef

Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708–33. doi:10.1542/peds.2004-2182.PubMedCrossRef

Biezeveld M, Geissler J, Merkus M, Kuipers IM, Ottenkamp J, Kuijpers T. The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease. Clin Exp Immunol 2007;147:106–11.PubMed

Shim YH, Kim HS, Sohn S, Hong YM. Insertion/deletion polymorphism of angiotensin converting enzyme gene in Kawasaki disease. J Korean Med Sci 2006;21:208–11.PubMedCrossRef

Minami T, Suzuki H, Takeuchi T, Uemura S, Sugatani J, Yoshikawa N. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. J Pediatr 2005;147:78–83. doi:10.1016/j.jpeds.2005.03.037.PubMedCrossRef

Huang FY, Chang TY, Chen MR, Hsu CH, Lee HC, Lin SP, et al. Genetic variations of HLA-DRB1 and susceptibility to Kawasaki disease in Taiwanese children. Hum Immunol 2007;68:69–74. doi:10.1016/j.humimm.2006.10.018.PubMedCrossRef

10.

Jin HS, Kim HB, Kim BS, Lee JK, Seo EJ, Yoo HW, et al. The IL-10 (-627 A/C) promoter polymorphism may be associated with coronary aneurysms and low serum albumin in Korean children with Kawasaki disease. Pediatr Res 2007;61:584–7.PubMed

11.

Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–7. doi:10.1016/S1074-7613(00)80165-X.PubMedCrossRef

12.

Desmetz C, Lin YL, Mettling C, Portales P, Rabesandeatana H, Clot J, et al. The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. Immunology 2006;119:551–61. doi:10.1111/j.1365-2567.2006.02470.x.PubMedCrossRef

13.

Burns JC, Shimizu C, Gonzalez E, Kulkarni H, Patel S, Shike H, et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 2005;192:344–9. doi:10.1086/430953.PubMedCrossRef

14.

Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. 1984.Tokyo, Japan: Ministry of Health and Welfare.

15.

Falcini F. Kawasaki disease. Curr Opin Rheumatol 2006;18:33–8. doi:10.1097/01.bor.0000197998.50450.f6.PubMedCrossRef

16.

Dominguez SR, Anderson MS, Glodé MP, Robinson CC, Holmes KV. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki syndrome. J Infect Dis 2006;194:1697-701. doi:10.1086/509509.PubMedCrossRef

17.

Ahn SY, Jang GC, Shin JS, Shin KM, Kim DS. Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea. Yonsei Med J 2003;44:1021–6.PubMed

18.

Wedderburn LR, Robinson N, Patel A, Varsani H, Woo P. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000;43:765–74. doi:10.1002/1529-0131(200004)43:4<765::AID-ANR7>3.0.CO;2-B.PubMedCrossRef

19.

Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 1999;11:553–9. doi:10.1093/intimm/11.4.553.PubMedCrossRef

20.

Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807–15. doi:10.1172/JCI5150.PubMedCrossRef

21.

Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998;101:746–54. doi:10.1172/JCI1422.PubMedCrossRef

22.

Mack M, Bruhl H, Gruber R, Jaeger C, Cihak J, Eiter V, et al. Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum 1999;42:981–8. doi:10.1002/1529-0131(199905)42:5<981::AID-ANR17>3.0.CO;2-4.PubMedCrossRef

23.

Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1 alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999;96:6873–8. doi:10.1073/pnas.96.12.6873.PubMedCrossRef

24.

Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996;35:3362–7. doi:10.1021/bi952950g.PubMedCrossRef

25.

Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379–85.PubMed

26.

Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108:388–92. doi:10.1016/S0022-3476(86)80878-2.PubMedCrossRef

27.

Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998;81:1116–20. doi:10.1016/S0002-9149(98)00116-7.PubMedCrossRef

28.

Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177–80. doi:10.1067/mpd.2000.107890.PubMedCrossRef

29.

Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, et al. Coronary risks after high dose gamma-globulin in children with Kawasaki disease. Pediatr Int 2000;42:464–9. doi:10.1046/j.1442-200x.2000.01288.x.PubMedCrossRef

30.

Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 2003;24:122–6. doi:10.1007/s00246-002-0063-1.PubMedCrossRef

31.

Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159:5946–55.PubMed

32.

Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001;184:940–3. doi:10.1086/323155.PubMedCrossRef

33.

Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 2001;104:860–3. doi:10.1161/hc3301.095286.PubMedCrossRef

34.

Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, et al. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002;105:766–9. doi:10.1161/hc0602.103396.PubMedCrossRef

35.

Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, et al. Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 1998;44:596–9. doi:10.1203/00006450-199810000-00021.PubMedCrossRef

36.

Asano T, Ogawa S. Expression of monocyte chemoattractant protein-1 in Kawasaki disease: the anti-inflammatory effect of gamma globulin therapy. Scand J Immunol 2000;51:98–103. doi:10.1046/j.1365-3083.2000.00650.x.PubMedCrossRef

37.

Freeman AF, Crawford SE, Finn LS, Lopez-Andreu JA, Ferrando-Monleon S, Perez-Tamarit D, et al. Inflammatory pulmonary nodules in Kawasaki disease. Pediatr Pulmonol 2003;36:102–6. doi:10.1002/ppul.10333.PubMedCrossRef

38.

Eberhard BA, Andersson U, Laxer RM, Rose V, Silverman ED. Evaluation of the cytokine response in Kawasaki disease. Pediatr Infect Dis J 1995;14:199–203. doi:10.1097/00006454-199503000-00006.PubMedCrossRef

39.

Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 1994;124:721–5. doi:10.1016/S0022-3476(05)81361-7.PubMedCrossRef

40.

Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 1992;121:924–6. doi:10.1016/S0022-3476(05)80343-9.PubMedCrossRef

Title: The CCR5 (−2135C/T) Polymorphism may be Associated with the Development of Kawasaki Disease in Korean Children
Authors: Won Kyoung Jhang
Mi-Jin Kang
Hyun-Seung Jin
Jinho Yu
Byoung-ju Kim
Bong Seong Kim
Jong-Keuk Lee
Eul-Ju Seo
Han-Wook Yoo
In Sook Park
Young Mi Hong
Soo-Jong Hong
Publication date: 01-01-2009
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 1/2009
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-008-9218-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Proinflammatory Cytokine Gene Polymorphisms among Iranian Patients with Asthma

In Vitro Differentiation of Human Monocytes into Dendritic Cells by Peptic–Tryptic Digest of Gliadin Is Independent of Genetic Predisposition and the Presence of Celiac Disease

The Clinical Spectrum of Leukocyte Adhesion Deficiency (LAD) III due to Defective CalDAG-GEF1

Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies

Interleukin-18 Binding Protein in the Sera of Patients with Wegener’s Granulomatosis

Higher Monocyte Expression of TLR2 and TLR4, and Enhanced Pro-inflammatory Synergy of TLR2 with NOD2 Stimulation in Sarcoidosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials